Analysts Rate Pfizer a Buy on Valuation Despite Omitting from Top 10 List

NEW YORK — Financial analysts at 24/7 Wall St. have issued a "Buy" rating for Pfizer Inc., assigning the pharmaceutical giant a price target of $32.72 per share, though the firm excluded the stock from its list of top 10 recommendations released Monday. The analysis, dated September 7, 2026, highlights a significant disparity between Pfizer's current market valuation and that of its industry peers as a primary driver for the positive outlook.

The analysts cited Pfizer's forward price-to-earnings (P/E) ratio of approximately nine times earnings as a key factor in their assessment. This metric places the stock at a meaningful discount relative to other major players in the pharmaceutical sector. The valuation gap suggests that the market may be undervaluing the company's current assets and future potential, creating an opportunity for investors seeking entry at lower price points.

Beyond valuation metrics, the report pointed to Pfizer's robust drug pipeline as a critical catalyst for future growth. The company continues to advance several key therapies through clinical trials, with analysts expecting upcoming data releases or regulatory approvals to bolster revenue streams in the coming fiscal years. Additionally, the firm noted Pfizer's attractive dividend yield, which provides income stability for shareholders while they await capital appreciation from new product launches.

Despite the "Buy" rating and the specific price target, the decision to omit Pfizer from the top 10 stocks list indicates a nuanced view of the company's immediate prospects. While the fundamentals support an investment thesis based on value and yield, the analysts appear to have identified other equities with stronger momentum or higher growth potential for their premier recommendations. This distinction suggests that while Pfizer represents a solid value play, it may not offer the explosive upside required to secure a spot among the sector's most aggressive picks.

The pharmaceutical landscape remains volatile as companies navigate post-pandemic demand shifts and patent expirations. Pfizer's ability to execute its pipeline strategy will be crucial in determining whether the stock can reach the $32.72 target set by analysts. Investors are now watching closely to see if trading volume increases following the report, or if the market continues to price the stock at a discount due to lingering concerns over revenue diversification.

The broader implications of this analysis remain to be seen as other financial institutions weigh in on Pfizer's trajectory for the remainder of 2026. Whether the "Buy" rating translates into sustained buying pressure or remains an isolated view depends on how quickly the company can demonstrate tangible progress in its development programs and maintain its competitive edge in a crowded therapeutic market.